On this page ▾
The market expects Ipca Labs to carry on much as it has.
At today’s share price, buyers are assuming Ipca Labs grows about 13% a year, forever. Over the last ten years it actually grew about 13% a year. The two are close, so the share price does not need the business to improve or to stumble. It needs it to keep doing roughly what it already does.
- How it is valued: Discounted cash flow.
- What the price assumes: 13% growth, against 13% the model takes from its own record.
- Ten-year record: Between FY2018 and FY2026, Ipca Labs' revenue went from ₹3,284 crore to ₹9,646 crore — it compounded at about 14% a year over 8 years.
- Biggest swing factor: India brands. Main risk: FDA issues.
01A Mumbai drugmaker with integrated APIs
Ipca Laboratories, run by the Godha family, sells branded medicines in India — pain relief brands such as Zerodol, anti-malarials and cardiovascular drugs — and makes many of its own active ingredients.
In 2023 it bought a majority stake in Unichem Laboratories, adding generics businesses in the US and Europe.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Ipca Labs, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Ipca Labs' record, in plain numbers
Between FY2018 and FY2026, Ipca Labs' revenue went from ₹3,284 crore to ₹9,646 crore — it compounded at about 14% a year over 8 years. Net profit grew from ₹239 crore to ₹1,184 crore, about 22% a year — faster than revenue, so margins widened. In FY2026 it kept 12.3% of revenue as net profit — against a low of 6.8% in FY2024 and a high of 21.1% in FY2021. The latest year added 7.9% to revenue, well behind its own long-run pace.
Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.
Revenue and net profit by year (₹ crore)
| Year | Revenue | Net profit | Margin |
|---|---|---|---|
| FY2018 | 3,284 | 239 | 7.3% |
| FY2019 | 3,773 | 442 | 11.7% |
| FY2020 | 4,649 | 604 | 13.0% |
| FY2021 | 5,420 | 1,141 | 21.1% |
| FY2022 | 5,830 | 890 | 15.3% |
| FY2023 | 6,244 | 479 | 7.7% |
| FY2024 | 7,705 | 523 | 6.8% |
| FY2025 | 8,940 | 785 | 8.8% |
| FY2026 | 9,646 | 1,184 | 12.3% |
04How Ipca Labs gets valued — and why
Discounted cash flowThis business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.
05What decides Ipca Labs' value
India brands
Pain and chronic therapies drive profit.
Unichem integration
Improving Unichem's margins adds value.
APIs
Ingredient sales follow global demand.
Exports
Branded and generic exports add growth.
06What could go wrong
- FDA issues. Plant inspections have affected US sales before.
- Price controls. Indian price caps limit some products.
- Integration. Unichem's turnaround may take time.
07What the full Ipca valuation shows
Sign in free to see the complete Ipca Labs valuation
- ✓Fair value per share — from a ten-year discounted cash flow, every step shown
- ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Ipca's value move
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Alkem, Torrent Pharma and other drugmakers
- ✓Downloadable report — the full write-up, yours to keep
08Questions people ask about Ipca Labs
What is Ipca known for?
Pain-relief and anti-malarial medicines and their ingredients.
What is Unichem Laboratories?
A drugmaker Ipca bought a majority of in 2023, with US and European generics.
Who runs Ipca?
The Godha family.
Is Ipca Labs overvalued?
At ₹1,884 the market is pricing in roughly 13% sustained growth, against the ~13% its own record supports. That is close to what it has delivered, so the price is broadly consistent with the company simply continuing as it has.
What is the intrinsic value of Ipca Labs?
It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.
How much debt does Ipca Labs carry?
Debt to equity stands at 0.01, down from 0.09 at the start of the period — the balance sheet is a core input to the cost of capital used here.